Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Younger unrelated donors may be preferable over HLA match in the PTCy era: a study from the ALWP of the EBMT

Blood (2024) 143 (24): 2534–2543.

https://doi.org/10.1182/blood.2023023697

Published: 2024

Includes: Supplemental data

Journal Articles

HLA Class I Mismatches Reduce Survival after HCT in the Ptcy Era: A Study By the EBMT Cellular Therapy and Immunobiology Working Party

Blood (2023) 142 (Supplement 1): 2178.

https://doi.org/10.1182/blood-2023-185945

Published: 2023

Journal Articles

A Novel, Closed-Line Mini Extracorporeal Photopheresis (ECP) Technique Using the Therakos TM CellEx TM Photopheresis System, Developed for Patients with Contraindications Against Conventional ECP Therapy

Andrea Várkonyi, Krisztián Kállay, Katalin Dobos, Szabolcs Tasnády, Péter Reményi, Marienn Reti

Blood (2023) 142 (Supplement 1): 6945.

https://doi.org/10.1182/blood-2023-181818

Published: 2023

Journal Articles

Prognostic Factors Impacting Post-Transplant Outcomes in Adult T-Cell Acute Lymphoblastic Leukemia: A Registry-Based Study By the EBMT Acute Leukemia Working Party

Blood (2023) 142 (Supplement 1): 2237.

https://doi.org/10.1182/blood-2023-180686

Published: 2023

Journal Articles

Trends in Allogeneic Stem Cell Transplantation for Good Risk Acute Myelogenous Leukemia in First Complete Remission: A Longitudinal Study of > 15 Years from the ALWP/EBMT

Blood (2023) 142 (Supplement 1): 3525.

https://doi.org/10.1182/blood-2023-174599

Published: 2023

Journal Articles

Cryopreserved Versus Non-Cryopreserved Peripheral Blood Haematopoietic Stem Cells for Autologous Stem Cell Transplantation in Multiple Myeloma: A Comparative Analysis from the Chronic Malignancies Working Party of EBMT and WBMT

Blood (2023) 142 (Supplement 1): 1034.

https://doi.org/10.1182/blood-2023-182808

Published: 2023

Journal Articles

Treosulfan-Based Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) for Patients with Myelodysplastic Syndrome (MDS): Comparative Analysis of a Randomized Controlled Trial and Real-World Data

Matthias Stelljes, Katja Sockel, Matthias Floeth, Johannes Schetelig, Martin Bornhäuser, Christian Reicherts, Georg Lenz, Thomas Schröder, Rudolf Trenschel, Miroslaw Markiewicz, Hélène Labussière-Wallet, Péter Reményi, Fabio Ciceri, Friedrich Stölzel

Blood (2023) 142 (Supplement 1): 3526.

https://doi.org/10.1182/blood-2023-180816

Published: 2023

Journal Articles

Improved Post-Transplant Outcomes in Recent Years for AML Patients with Intermediate Karyotype, FLT3 -ITD and Wild Type NPM1 : A Report from the EBMT Acute Leukemia Working Party

Ali Bazarbachi, Myriam Labopin, Tobias Gedde-Dahl, Péter Reményi, Edouard Forcade, Nicolaus Kröger, Gerard Socie, Charles Craddock, Jean-Henri Bourhis, Jurjen Versluis, Ibrahim Yakoub-Agha, Urpu Salmenniemi, Jean Elcheikh, Gesine Bug, Jordi Esteve, Arnon Nagler, Fabio Ciceri, Mohamad Mohty

Blood (2022) 140 (Supplement 1): 4897–4898.

https://doi.org/10.1182/blood-2022-165069

Published: 2022

Journal Articles

Risk Factors Influencing Transplant Outcomes of Adults with Acute Lymphoblastic Leukemia in First Complete Remission: A Retrospective Analysis from the ALWP of the EBMT

Blood (2022) 140 (Supplement 1): 4870–4871.

https://doi.org/10.1182/blood-2022-166081

Published: 2022

Journal Articles

Artificial Intelligence Methods to Estimate Overall Mortality and Non-Relapse Mortality Following Allogeneic Hematopoietic Cell Transplantation in the Modern Era: An EBMT Transplant Complications Working Party Study

Blood (2022) 140 (Supplement 1): 7734–7737.

https://doi.org/10.1182/blood-2022-168601

Published: 2022

Journal Articles

Characteristics and Outcomes of Newly Diagnosed Multiple Myeloma Patients with and without Extramedullary Disease after Autologous Transplant and Maintenance Therapy: A Study from the Cmwp-EBMT

Blood (2021) 138 (Supplement 1): 485.

https://doi.org/10.1182/blood-2021-152391

Published: 2021

Journal Articles

Higher Efficacy of TBI + Cyclophosphamide Than TBI + Fludarabine As Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia: An Analysis By the Acute Leukemia Working Party of the EBMT

Blood (2021) 138 (Supplement 1): 2876.

https://doi.org/10.1182/blood-2021-151000

Published: 2021

Journal Articles

Transplant Outcomes in Patients with Ph+ Chronic Myeloid Leukemia: Haploidentical Donors Compared to Matched Sibling Donors and Matched/Mismatched Unrelated Donors: A Retrospective Analysis from the EBMT Chronic Malignancies Working Party (EBMT-CMWP)

Blood (2021) 138 (Supplement 1): 3959.

https://doi.org/10.1182/blood-2021-146366

Published: 2021

Journal Articles

Allogeneic Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia (AML) in Second Complete Remission (CR2) Transplanted from Unrelated Donors with Post Transplant Cyclophosphamide (PTCy). a Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Arnon Nagler, Myriam Labopin, Aleksandr D. Kulagin, Hélène Labussière-Wallet, Montserrat Rovira, Didier Blaise, Jan Vydra, Ibrahim Yakoub-Agha, Goda Choi, Yener Koc, Péter Reményi, Fabio Ciceri, Jaime Sanz, Mohamad Mohty

Blood (2021) 138 (Supplement 1): 3916.

https://doi.org/10.1182/blood-2021-144894

Published: 2021

Journal Articles

A Novel Early Relapse Prediction Score Based on Age, ISS and Disease Status at the Time of Transplant in Patients with Newly Diagnosed Multiple Myeloma. a Study of the EBMT Chronic Malignancies Working Party

Blood (2021) 138 (Supplement 1): 3937.

https://doi.org/10.1182/blood-2021-147001

Published: 2021

Journal Articles

Comparison of Different Upfront Transplant Strategies in Multiple Myeloma - a Large Registry Study from Chronic Malignancies Working Party of EBMT

Blood (2019) 134 (Supplement_1): 324.

https://doi.org/10.1182/blood-2019-128795

Published: 2019

Journal Articles

Comparison of a New Reduced Toxicity Myeloablative Treosulfan and Fludarabine Preparative Regimen with Myeloablative Busulfan or Melphalan in Combination with Fludarabine in Older Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes: A Retrospective Matched Pair Analysis of Patients from a Prospective Randomized Trial and the European Blood and Marrow Transplantation Society Registry

Dietrich W. Beelen, Simona Iacobelli, Linda Koster, Dirk-Jan Eikema, Anja van Biezen, Friedrich Stoelzel, MD, Fabio Ciceri, MD, Wolfgang Bethge, Peter Dreger, Eva-Maria Wagner, Péter Reményi, Matthias Stelljes, Miroslaw Markiewicz

Blood (2019) 134 (Supplement_1): 3326.

https://doi.org/10.1182/blood-2019-127108

Published: 2019

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia and Karnofsky Performance Status Score Equal or Lower Than 80%. a Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Francesco Saraceni, Myriam Labopin, MD, Riitta Niittyvuopio, Gerard Socie, MD PhD, Nicolaus Kröger, Edouard Forcade, MD, Paul V Browne, MB,FRCPath, Péter Reményi, Jan J Cornelissen, MD PhD, Stephen Robinson, MBBS, PhD BSc, Ibrahim Yakoub-Agha, MD PhD, Thierry Lamy, PhD MD, Eolia Brissot, MD PhD, Bipin N. Savani, MD, Arnon Nagler, MD MSc, Mohamad Mohty, MD PhD

Blood (2019) 134 (Supplement_1): 3327.

https://doi.org/10.1182/blood-2019-127810

Published: 2019

Journal Articles

Impact of Donor-Derived CD34+ Infused Cell Dose on Outcomes of Patients Undergoing Allo-HCT Following Reduced Intensity Regimen for Myelofibrosis:a Study from the Chronic Malignancies Working Party of the EBMT

Blood (2019) 134 (Supplement_1): 3338.

https://doi.org/10.1182/blood-2019-123827

Published: 2019

Journal Articles

Trends in Autologous Transplantation for Myeloma in EBMT Centres between 1993 and 2017

Blood (2019) 134 (Supplement_1): 4575.

https://doi.org/10.1182/blood-2019-127166

Published: 2019

NARROW

Younger unrelated donors may be preferable over HLA match in the PTCy era: a study from the ALWP of the EBMT

HLA Class I Mismatches Reduce Survival after HCT in the Ptcy Era: A Study By the EBMT Cellular Therapy and Immunobiology Working Party

A Novel, Closed-Line Mini Extracorporeal Photopheresis (ECP) Technique Using the Therakos TM CellEx TM Photopheresis System, Developed for Patients with Contraindications Against Conventional ECP Therapy

Prognostic Factors Impacting Post-Transplant Outcomes in Adult T-Cell Acute Lymphoblastic Leukemia: A Registry-Based Study By the EBMT Acute Leukemia Working Party

Trends in Allogeneic Stem Cell Transplantation for Good Risk Acute Myelogenous Leukemia in First Complete Remission: A Longitudinal Study of > 15 Years from the ALWP/EBMT

Cryopreserved Versus Non-Cryopreserved Peripheral Blood Haematopoietic Stem Cells for Autologous Stem Cell Transplantation in Multiple Myeloma: A Comparative Analysis from the Chronic Malignancies Working Party of EBMT and WBMT

Treosulfan-Based Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) for Patients with Myelodysplastic Syndrome (MDS): Comparative Analysis of a Randomized Controlled Trial and Real-World Data

Improved Post-Transplant Outcomes in Recent Years for AML Patients with Intermediate Karyotype, FLT3 -ITD and Wild Type NPM1 : A Report from the EBMT Acute Leukemia Working Party

Risk Factors Influencing Transplant Outcomes of Adults with Acute Lymphoblastic Leukemia in First Complete Remission: A Retrospective Analysis from the ALWP of the EBMT

Artificial Intelligence Methods to Estimate Overall Mortality and Non-Relapse Mortality Following Allogeneic Hematopoietic Cell Transplantation in the Modern Era: An EBMT Transplant Complications Working Party Study

Characteristics and Outcomes of Newly Diagnosed Multiple Myeloma Patients with and without Extramedullary Disease after Autologous Transplant and Maintenance Therapy: A Study from the Cmwp-EBMT

Higher Efficacy of TBI + Cyclophosphamide Than TBI + Fludarabine As Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia: An Analysis By the Acute Leukemia Working Party of the EBMT

Transplant Outcomes in Patients with Ph+ Chronic Myeloid Leukemia: Haploidentical Donors Compared to Matched Sibling Donors and Matched/Mismatched Unrelated Donors: A Retrospective Analysis from the EBMT Chronic Malignancies Working Party (EBMT-CMWP)

A Novel Early Relapse Prediction Score Based on Age, ISS and Disease Status at the Time of Transplant in Patients with Newly Diagnosed Multiple Myeloma. a Study of the EBMT Chronic Malignancies Working Party

Comparison of Different Upfront Transplant Strategies in Multiple Myeloma - a Large Registry Study from Chronic Malignancies Working Party of EBMT

Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia and Karnofsky Performance Status Score Equal or Lower Than 80%. a Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Impact of Donor-Derived CD34+ Infused Cell Dose on Outcomes of Patients Undergoing Allo-HCT Following Reduced Intensity Regimen for Myelofibrosis:a Study from the Chronic Malignancies Working Party of the EBMT

Trends in Autologous Transplantation for Myeloma in EBMT Centres between 1993 and 2017

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only